Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.

Saved in:
Bibliographic Details
Title: Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.
Authors: Rodriguez GC; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, United States. Electronic address: grodriguez@northshore.org., Turbov J; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States., Rosales R; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States., Yoo J; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States., Hunn J; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, United States., Zappia KJ; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States., Lund K; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States., Barry CP; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States., Rodriguez IV; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States., Pike JW; Department of Biochemistry, University of Wisconsin, Madison, WI, United States., Conrads TP; Gynecologic Cancer Center of Excellence, Annandale, VA, United States; Inova Schar Cancer Institute, Inova Center for Personalized Health, 3300 Gallows Road, Falls Church, VA, United States., Darcy KM; Gynecologic Cancer Center of Excellence, Annandale, VA, United States; Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine, Inova Medical Campus, Falls Church, VA, United States., Maxwell GL; Gynecologic Cancer Center of Excellence, Annandale, VA, United States; Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, VA, United States; Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine, Inova Medical Campus, Falls Church, VA, United States., Hamilton CA; Gynecologic Cancer Center of Excellence, Annandale, VA, United States; Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States; Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, MD, United States., Syed V; Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States; Department of Molecular and Cell Biology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States., Thaete LG; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, United States; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, United States.
Source: Gynecologic oncology [Gynecol Oncol] 2016 Oct; Vol. 143 (1), pp. 159-167. Date of Electronic Publication: 2016 Jul 29.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1095-6859
DOI:10.1016/j.ygyno.2016.04.022